Chordia Therapeutics Inc. · TSE:190A
Chordia Therapeutics — FY2026 Earnings Presentation
27 slides from Chordia Therapeutics's earnings presentation, Oct 15, 2026
Slide 1: Fiscal year ended August 2026 Financial Results Presentation
Fiscal year ended August 2026 Financial Results Presentation Chordia Therapeutics Inc. (TSE securities code: 190A) October 15, 2026
Slide 2: Table of Contents
Table of Contents 1. Corporate Overview P. 3 2. FY2026 Highlights and Review P. 6 3. FY2026 Financial Results and Financial Position P. 9 4. Pipeline Progress P. 14 5． Key Priorities for FY2027 P. 23 Chordia Therapeutics Inc. 2
Slide 3: Corporate Overview and Business History
Corporate Overview and Business History Company Name Chordia Therapeutics Inc Establishment October,12,2017 Head Office Fujisawa, Kanagawa, Japan Paid-in Capital ¥1,345 million Profile Securities code 190A Representative Hiroshi Miyake Employees 22 personnel (incl, 12 PhD) Total Funding Raised Appro
Slide 4: Management Team Driving Growth with Diverse Expertise
Management Team Driving Growth with Diverse Expertise ⚫CEO and expert external directors driving growth through agile decision-making Audit and Supervisor Representative External Director Committee member (External Director) Strategy Accounting Manabu Nakamura （Representative Director, Shinsei Capit
Slide 5: Table of Contents
Table of Contents 1. Corporate Overview P. 3 2. FY2026 Highlights and Review P. 6 3. FY2026 Financial Results and Financial Position P. 9 4. Pipeline Progress P. 14 5． Key Priorities for FY2027 P. 23 Chordia Therapeutics Inc. 5
Slide 6: Advancing R&D and Strengthening Our Business Foundation
Advancing R&D and Strengthening Our Business Foundation R&D rogocekib CTX-439 Japan Japan CTX-439 Joint Research OrphanDrug Orphan DrugDesignation Designation with Kyoto University Clinical Trials Clinical Trials forRelapsed for RelapsedororRefractory RefractoryAML AML Paper Published Total 129 Tota
Slide 7: FY2026 Review
FY2026 Review Achieved Not Achieved Achieved Clinical trial progress for approval Proactively engage in new Properly execute disclosure to of rogocekib (CTX-712) business alliances shareholders ・Initiation of expansion cohort in U.S. CTX-177 is a priority for re-licensing and Research progress will
Slide 8: Table of Contents
Table of Contents 1. Corporate Overview P. 3 2. FY2026 Highlights and Review P. 6 3. FY2026 Financial Results and Financial Position P. 9 4. Pipeline Progress P. 14 5． Key Priorities for FY2027 P. 23 Chordia Therapeutics Inc. 8
Slide 9: FY2026 Financial Results (Statement of Income)
FY2026 Financial Results (Statement of Income) ⚫R&D expenses decreased year on year: U.S. CRO costs rose with the initiation of the expansion cohort, but manufacturing-related costs were limited as the drug substance and drug product required for the trial had already been secured. Unit：Million Yen
Slide 10: FY2026 Financial Position (Balance Sheet)
FY2026 Financial Position (Balance Sheet) ⚫Financing through the exercise of the 9th Series Stock Acquisition Rights brought cash and deposits to ¥2,052 million as of August 31, 2026, securing the funds required for business activities over the next 12 months and maintaining the financial foundation
Slide 11: Financing through the 12th Series Stock Acquisition Rights
Financing through the 12th Series Stock Acquisition Rights ●Following the securing of operating funds for the next year, Chordia completed additional financing to maintain flexibility for the completion of the rogocekib expansion cohort, Phase 2 preparation and future development activities, while f
Slide 12: AMED GRIT Program Selected
AMED GRIT Program Selected ● rogocekib global clinical development program selected for AMED’s GRIT program, with expected support of up to ¥1.5 billion. Project Details About GRiT ■ Program FY2026 AMED “Innovative Medical Technology Research and An AMED initiative that supports global clinical tria
Slide 13: Table of Contents
Table of Contents 1. Corporate Overview P. 3 2. FY2026 Highlights and Review P. 6 3. FY2026 Financial Results and Financial Position P. 9 4. Pipeline Progress P. 14 5． Key Priorities for FY2027 P. 23 Chordia Therapeutics Inc. 13
Slide 14: Of the five pipelines, two are in the clinical stage
Of the five pipelines, two are in the clinical stage ― Strategic focus on rogocekib, which has high market potential, to accelerate value creation ⚫Focus resources on rogocekib and advance development in Japan and the U.S. through in-house development or partnerships. ⚫Assess monetization opportunit
Slide 15: Rogocekib CTX-712 (CLK): Advancing the Expansion Cohort
rogocekib update rogocekib update Rogocekib CTX-712 (CLK) : Advancing the Expansion Cohort Objectives of Determine recommended dose and target indications based on safety and expansion cohort efficacy evaluation Aligned with Expansion Cohort FDA Project Optimus Safety Dose-escalation cohort IE cohor
Slide 16: rogocekib: Overview of Interim Results Presented at EHA 2026
rogocekib update rogocekib：Overview of Interim Results Presented at EHA 2026 ⚫Presented data from the dose-escalation cohort in patients with relapsed/refractory myeloid malignancies who have limited treatment options. Patient Characteristics (n=42)― Predominantly elderly patients with Presentation
Slide 17: rogocekib: Safety (EHA 2026)
rogocekib update rogocekib（26年８月期進捗） rogocekib：Safety (EHA 2026) ⚫A manageable safety profile was observed, with gastrointestinal adverse events being the most common and hematologic toxicities remaining limited. Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicities (DLT) Frequency of Major Adve
Slide 18: rogocekib: Efficacy (EHA 2026)
rogocekib（26年８月期進捗） rogocekib update rogocekib：Efficacy (EHA 2026) ⚫Single-agent antitumor activity was observed in patients with relapsed or refractory disease. 11.8% 29Days 157Days Overall Response Rate (ORR)： Median Time to Response Median Duration of Response 4 of 34 evaluable patients Responses
Slide 19: Development Milestones for rogocekib
rogocekib update Development Milestones for rogocekib ― Steady Progress with 129 Patient Enrollments Across Japan and the U.S. ⚫Patient enrollment in the clinical trials continues to progress steadily, with a total of 129 patients enrolled in Japan and the U.S. as of August 31, 2026. In addition to
Slide 20: Monetization Strategy and Focus
Strategy Monetization Strategy and Focus ―Strategy (shortened timelines) × Focus (small molecules, first-in-class, precision) ⚫ Accelerated value creation by shifting focus from discovery to clinical research, significantly shortening development timelines ⚫ Risk reduction and higher returns through
Slide 21: Diversified Capital Strategy under Uncertainty
Strategy Diversified Capital Strategy under Uncertainty ⚫As clinical data accumulates in Japan and the U.S. (reducing risk and uncertainty while increasing value), a broader range of capital strategy options becomes available. Value Advancing development expands partnership and financing opportuniti
Slide 22: Table of Contents
Table of Contents 1. Corporate Overview P. 3 2. FY2026 Highlights and Review P. 6 3. FY2026 Financial Results and Financial Position P. 9 4. Pipeline Progress P. 14 5． Key Priorities for FY2027 P. 23 Chordia Therapeutics Inc. 22
Slide 23: Key Priorities for FY2027
Key Priorities for FY2027 ● Advance the development of rogocekib toward initiation of a Phase 2 clinical trial, while maintaining optionality including strategic partnerships to maximize value. 1 Development 2 Business Development 3 Financial Foundation Development of rogocekib toward Business Devel
Slide 24: Building a world where tomorrow is another day!
Management policies and 2030 vision Building a world where tomorrow is another day! Delivering the world’s first made-in-Japan new anticancer drugs to patients as soon as possible Mission We are passionate to deliver first-in-class cancer drugs to patients. 2030 Vision To be an R&D-oriented pharmace
Slide 25: Four compound patents supported by multiple use and process patents
Appendix Common update Four compound patents supported by multiple use and process patents ⚫In addition to holding compound patents licensed from Takeda Pharmaceutical with sufficient remaining term, we are actively securing intellectual property rights for clinical-stage programs through the acquis
Slide 26: Disclaimer
Disclaimer ⚫ This presentation has been prepared solely for the purpose of presenting relevant information regarding Chordia Therapeutics Inc. (the “Company” or “Chordia”). This presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicita
Slide 27: Chordia Therapeutics Inc.
Chordia Therapeutics Inc. 27